He FZ - Search Results

1

Epigenetic perspectives on cancer chemotherapy response.

Liu MZ, McLeod HL, He FZ, Chen XP, Zhou HH, Shu Y, Zhang W. Liu MZ, et al. Among authors: he fz. Pharmacogenomics. 2014 Apr;15(5):699-715. doi: 10.2217/pgs.14.41. Pharmacogenomics. 2014. PMID: 24798726 Review.

2

Current pharmacogenomic studies on hERG potassium channels.

He FZ, McLeod HL, Zhang W. He FZ, et al. Trends Mol Med. 2013 Apr;19(4):227-38. doi: 10.1016/j.molmed.2012.12.006. Epub 2013 Jan 29. Trends Mol Med. 2013. PMID: 23369369 Review.

3

The KCNH2 genetic polymorphism (1956, C>T) is a novel biomarker that is associated with CCB and α,β-ADR blocker response in EH patients in China.

He F, Luo J, Luo Z, Fan L, He Y, Zhu D, Gao J, Deng S, Wang Y, Qian Y, Zhou H, Chen X, Zhang W. He F, et al. PLoS One. 2013 Apr 22;8(4):e61317. doi: 10.1371/journal.pone.0061317. Print 2013. PLoS One. 2013. PMID: 23613831 Free PMC article.

4

Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan.

Chen WQ, Shu Y, Li Q, Xu LY, Roederer MW, Fan L, Wu LX, He FZ, Luo JQ, Tan ZR, He YJ, Zhou HH, Chen X, Zhang W. Chen WQ, et al. Among authors: he fz, he yj. PLoS One. 2013 Aug 5;8(8):e70341. doi: 10.1371/journal.pone.0070341. Print 2013. PLoS One. 2013. PMID: 23940561 Free PMC article. Clinical Trial.

5

Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment.

Luo JQ, Wang LY, He FZ, Sun NL, Tang GF, Wen JG, Luo ZY, Liu ZQ, Zhou HH, Chen XP, Zhang W. Luo JQ, et al. Among authors: he fz. Pharmacogenomics. 2014 Feb;15(2):201-8. doi: 10.2217/pgs.13.173. Epub 2013 Sep 23. Pharmacogenomics. 2014. PMID: 24059494

6

[Epigenetic research progress of anti-tumor drugs].

Liu MZ, He FZ, Zhang W. Liu MZ, et al. Among authors: he fz. Yao Xue Xue Bao. 2013 Nov;48(11):1629-36. Yao Xue Xue Bao. 2013. PMID: 24475698 Review. Chinese.

7

Rs495828 polymorphism of the ABO gene is a predictor of enalapril-induced cough in Chinese patients with essential hypertension.

Luo JQ, He FZ, Luo ZY, Wen JG, Wang LY, Sun NL, Tang GF, Li Q, Guo D, Liu ZQ, Zhou HH, Chen XP, Zhang W. Luo JQ, et al. Among authors: he fz. Pharmacogenet Genomics. 2014 Jun;24(6):306-13. doi: 10.1097/FPC.0000000000000050. Pharmacogenet Genomics. 2014. PMID: 24743543

8

Pharmacogenomics and herb-drug interactions: merge of future and tradition.

Liu MZ, Zhang YL, Zeng MZ, He FZ, Luo ZY, Luo JQ, Wen JG, Chen XP, Zhou HH, Zhang W. Liu MZ, et al. Among authors: he fz. Evid Based Complement Alternat Med. 2015;2015:321091. doi: 10.1155/2015/321091. Epub 2015 Mar 2. Evid Based Complement Alternat Med. 2015. PMID: 25821484 Free PMC article. Review.

9

The RGS2 (-391, C>G) genetic variation correlates to antihypertensive drug responses in Chinese patients with essential hypertension.

He F, Luo J, Zhang Z, Luo Z, Fan L, He Y, Wen J, Zhu D, Gao J, Wang Y, Qian Y, Zhou H, Chen X, Zhang W. He F, et al. PLoS One. 2015 Apr 7;10(4):e0121483. doi: 10.1371/journal.pone.0121483. eCollection 2015. PLoS One. 2015. PMID: 25849301 Free PMC article. Clinical Trial.

10

Pharmacogenomics research: a potential strategy for drug development.

Wen JG, Wu L, Pu XX, He FZ, Liu MZ, Zhou HH, Zhang W. Wen JG, et al. Among authors: he fz. Pharmazie. 2015 Jul;70(7):437-45. Pharmazie. 2015. PMID: 26373203 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

42 results

Search Page